Get 50% OFF This Summer!

Advertisement
logo

Shukra Pharmaceuticals

524632
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Shukra Pharmaceuticals Share price and Fundamental Analysis

View All Details
View All Details
Shukra Pharmaceuticals Ltd (Formerly known Relish Pharmaceuticals Limited) was established in March 1993 and later on the name of Company got changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on 22 September, 2016. The Company is presently engaged in the business of manufacturing of pharmaceuticals Products and laboratory testing.
Company Incorporation1993
ChairmanDakshesh Shah
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
635.8
PE Ratio
76.42
Industry P/E
35.21
PEG Ratio
0.22
ROE
26.59%
ROCE
29.28%
ROA
10.14%
Total Debt (Cr)
2.73
Debt to Equity
0.05
Dividend Yield
0.17%
EPS
0.19
Book Value & P/B
1.24 x 11.71
Face Value
1
Outstanding Shares(Cr)
43.79
Current Ratio
2.94
EV to Sales
20.55

Included In

+More

Stock Returns

1 Week+2.12%
1 Month-31.87%
6 Months+122.97%
1 Year+18.17%
3 Years+4560%
5 Years+8637.5%

CAGR

1 Year CAGR

Revenue Growth

+26.75%

Net Profit Growth

+320.68%

Operating Profit Growth

+238.7%

Dividend Growth

+100%

Stock Returns CAGR

+20.4%
no_data

No Stocks

Smart Score

3.3
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Profit and Loss Statement

Credit Rating
Director Report
Chairman Report
Auditor Report
Mar 25

Promoters : 50.96%

FIIs : 0.00%

DIIs : 0.11%

Public : 48.93%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Shukra Pharmaceuticals Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Shukra Pharmaceuticals Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Shukra Pharmaceuticals Ltd (Formerly known Relish Pharmaceuticals Limited) was established in March 1993 and later on the name of Company got changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on 22 September, 2016. The Company is presently engaged in the business of manufacturing of pharmaceuticals Products and laboratory testing.

The company provides varieties of products to the clientele. Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

The company has four manufacturing divisions namely tablets (General and Beta Lactum) Capsules (General and Beta Lactum), Liquid and small volume parental. Their manufacturing unit is located at Rakanpur in Gujarat.

The company customers include leading Manufacturers like Cadila Healthcare Limited (Zydus), Intas Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Makers Laboratories Limited, Agenta Pharma Limited etc.

The company has assisted in the development and manufacture of a wide variety of drugs and dosage forms and potency variations for many prestigious pharmaceuticals companies around the world.

In FY 2013-14, the Company got approval from Hon'ble High Court of Gujarat for revival of Relish Pharmaceuticals Limited and Amalgamation of Proper Dealcomm Private Limited (Transferor Company) with Relish Pharmaceuticals Limited (Transferee Company) and Re-organization of Share Capital of Relish Pharmaceuticals Limited (Transferee Company) through Scheme of Arrangement vide Hon'ble High Court of Gujarat order dated 20 Dec' 2013.

Shukra Pharmaceuticals Share Price

Shukra Pharmaceuticals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Shukra Pharmaceuticals Market Cap

Market capitalization of Shukra Pharmaceuticals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Shukra Pharmaceuticals is valued compared to its competitors.

Shukra Pharmaceuticals PE Ratio

Shukra Pharmaceuticals PE ratio helps investors understand what is the market value of each stock compared to Shukra Pharmaceuticals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Shukra Pharmaceuticals PEG Ratio

The PEG ratio of Shukra Pharmaceuticals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Shukra Pharmaceuticals ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Shukra Pharmaceuticals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Shukra Pharmaceuticals ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Shukra Pharmaceuticals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Shukra Pharmaceuticals Total Debt

Total debt of Shukra Pharmaceuticals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Shukra Pharmaceuticals Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Shukra Pharmaceuticals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Shukra Pharmaceuticals CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Shukra Pharmaceuticals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Shukra Pharmaceuticals Technical Analysis

Technical analysis of Shukra Pharmaceuticals helps investors get an insight into when they can enter or exit the stock. Key components of Shukra Pharmaceuticals Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Shukra Pharmaceuticals shares often struggle to rise above due to selling pressure.

Shukra Pharmaceuticals Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Shukra Pharmaceuticals ’s financial health and profitability.

Shukra Pharmaceuticals Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Shukra Pharmaceuticals Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Shukra Pharmaceuticals Financials

The financials of Shukra Pharmaceuticals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Shukra Pharmaceuticals Profit and Loss Statements

The profit and loss statement of Shukra Pharmaceuticals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Shukra Pharmaceuticals .

Shukra Pharmaceuticals Balance Sheet

The balance sheet presents a snapshot of Shukra Pharmaceuticals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Shukra Pharmaceuticals Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App